Alluvi, previously known as LY3414901, represents a significant advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable effectiveness in early clinical data, with conside